|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
RGD |
Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.
|
20733093 |
2010 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
|
11425780 |
2001 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension.
|
12600921 |
2003 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1 has been associated with development of hypoxia-related pulmonary hypertension and vascular endothelial growth factor (VEGF) with protection from this complication.
|
16769575 |
2006 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Endothelin-1 gene and endothelial nitric oxide synthase gene polymorphisms in adolescents with juvenile and obesity-associated hypertension.
|
17444275 |
2007 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1 (ET-1) promotes vasoconstriction and cell proliferation, and has been implicated in hypertension and coronary artery disease.
|
19672034 |
2009 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1 impairs angiogenesis in vitro through Rho-kinase activation after chronic intrauterine pulmonary hypertension in fetal sheep.
|
23202724 |
2013 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1 (ET-1) plays a major role in regulating myocardial fibrosis in several pathological conditions, such as hypertension and diabetes.
|
25584774 |
2015 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1 is implicated in the pathogenesis of hypertension, but the underlying mechanisms remained elusive.
|
28750371 |
2017 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1 (ET-1), as it functions as a neuromodulator, has been associated with hypertension in chronic intermittent hypoxia (CIH) which attribute to enhanced carotid body sensibility to hypoxia.
|
30579678 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1 (ET-1) is a potential contributor to sex differences in the pathophysiology of hypertension.
|
30606254 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1/nitric oxide balance and HOMA index in children with excess weight and hypertension: a pathophysiological model of hypertension.
|
30923371 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin 1 Is Associated with Heart Failure Hospitalization and Long-Term Mortality in Patients with Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension.
|
31514181 |
2020 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1 (ET-1) is a powerful vasoconstrictor peptide considered to be causally implicated in hypertension and the development of cardiovascular disease.
|
31630572 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Endothelin-1 infusion into humans to obtain pathophysiological plasma levels causes mild hypertension, strong renal vasoconstriction, and sodium retention.
|
7721406 |
1995 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1-selective receptor in the arterial intima of patients with hypertension.
|
8125552 |
1994 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
A gene polymorphism in EDN1, Lys198Asn, has been reported to be associated with hypertension in obese subjects.
|
17664854 |
2007 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
AAV Delivery of Endothelin-1 shRNA Attenuates Cold-Induced Hypertension.
|
27736201 |
2017 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
AAV vector-mediated CRP expression resulted in hypertension mediated through reduced NO production and subsequent alteration in ET-1 and renin-angiotensin system activation.
|
19056836 |
2009 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Adrenocorticotrophic hormone-induced hypertension in the rat: effects of the endothelin antagonist bosentan.
|
10474778 |
1999 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Although it has been found that systemic induction of heme oxygenase (HO)-1 is associated with reduced ET-1 production and attenuated hypertension, it is unclear whether HO-1 directly modulates the increased ET-1 response to placental factors.
|
29212810 |
2018 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Ambrisentan is a highly selective endothelin-1 type A receptor antagonist indicated for use in the treatment of pulmonary hypertension.
|
29289894 |
2018 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
AT1-AA has been shown to enhance the effect of AngII in pre-eclampsia, such as production of endothelin-1, activation of ROS, and vasoconstriction, which are considered to be associated with hypertension; however, whether or not AT1-AA participates in podocyte damage leading to the generation of proteinuria has not been reported.
|
30380548 |
2018 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Based on both in-vivo and in-vitro data, we have shown a potential causal association between Arg(972) IRS-1 and elevated plasma ET-1 level in hypertensives, which may account for the aggravated hypertension observed in hypertensives with heterozygous Arg(972) IRS-1.
|
22759779 |
2012 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Based on the principle of Cochrane systematic reviews, case control studies (CCSs) in PubMed (Medline) and Google Scholar designed to identify the role of endothelin-1 (ET-1) in the pathophysiological of hypertension were screened.
|
28531898 |
2017 |